Featured

Hello, India!

This featured post is about ChartAlert, a Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software

1–2 minutes

ChartAlert® is a Microsoft® Windows® compatible Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software that complements your trading and investing needs.

ChartAlert features three seamless modules.

1. The Charting module includes Charting and Masks.

2. The Reporting module includes Basic Advisory Content and Market Reports.

3. The Scanning module includes Basic Scanner, Advanced Scanner, RS Matrix & Trend Matrix, Trading Systems Builder and the Backtester.

Continue reading “Hello, India!”

India’s 20 years of GDP misestimation: New evidence (PIIE)

The authors — Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics) — imply India’s post-2011 GDP growth was structurally overstated by ~1.5–2.0% due to deflator and informal-sector mismeasurement, forcing investors to haircut cyclical exposures, reassess consumption-driven bets, and price in policy recalibration risks.

1–2 minutes

Based on the paper “India’s 20 years of GDP misestimation: New evidence” by authors Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics).

 The authors — Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics) — imply India’s post-2011 GDP growth was structurally overstated by ~1.5–2.0% due to deflator and informal-sector mismeasurement, forcing investors to haircut cyclical exposures, reassess consumption-driven bets, and price in policy recalibration risks.

Continue reading “India’s 20 years of GDP misestimation: New evidence (PIIE)”

MUTHOOTFIN – Q3 FY26 Earnings Call – 12-Feb-26

MUTHOOTFIN: Gold loan structural tailwinds and regulatory support underpin 18–22% AUM growth, but earnings quality hinges on NPA recovery sustainability and opex discipline; margins face 50–100 bps compression if cost inflation outpaces revenue, while competitive and macro risks cap upside to low-teens EPS growth.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Gold prices stable (±5%), MCLR pass-through in H2, regulated branch growth.
Outcome: AUM grows 18–22%, NIM stable at ~7.5% (recoveries offset funding lag). Opex growth moderates to 15%, margins 26–28%. EPS grows 8–12%, driven by gold loan dominance and subsidiary turnarounds. Guidance clarity supports valuation rerating.

Continue reading “MUTHOOTFIN – Q3 FY26 Earnings Call – 12-Feb-26”

ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26

ZYDUSLIFE’s topline: 12–15% CAGR driven by US specialty, India chronic portfolio, and International Markets; Bottomline: 8–10% EPS growth contingent on margin stability and R&D efficiency; Margins: 23–25% EBITDA range, with upside from biosimilar scaling and downside from acquisition dilution.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Mirabegron settlement; CDMO revenue ramp-up in H2 FY27; biosimilar launches on schedule.
  • Outcome: US revenue grows 8–10% YoY, driven by specialty and generics volume. EBITDA margins stabilize at 23–25%. India and International Markets sustain 15–20% growth. Net debt reduces to ₹2,500Cr by FY28 as cash flows improve. GLP-1 captures 10–15% market share in India.
Continue reading “ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26”

DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26

DIVISLAB’s growth relies on CS (57% mix), with generics resilient but pressured by pricing. Bottomline depends on CS commercialization (CY27) and cost pass-through, while margins face labor/raw material volatility, partly offset by backward integration and automation over 2–3 years.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) 2/3 CS projects commercialize in Q3–Q4 CY27; (2) Generic pricing stabilizes (China’s rebate removal lifts API prices by 3–5%). Outcome: Revenue 8–10% CAGR, EBITDA margins expand 50 bps (CS mix shift), and gross asset turnover improves to 1.4x by FY28. EPS grows 8–12% annually.

Continue reading “DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26”

TITAGARH – Q3 FY26 Earnings Call – 16-Feb-26

Passenger rail to drive 70%+ growth (18–25% CAGR), while freight lags; high-speed rail and MRVC remain wildcards. TITAGARH’s EBITDA margins could reach 13–15% by FY’28 with backward integration, but freight volatility and execution risks loom. Passenger scale and aluminium integration are margin-critical; freight stable yet input-sensitive.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Freight tenders materialize in Q1 FY’27 (800–1,000 wagons/month); metro production hits 18–20 cars/month by FY’27; 1–2 high-speed rail contracts secured.
  • Outcome: Revenue CAGR of 18–22%, with Passenger Rail Systems contributing 60%+ of EBITDA by FY’28. Margins expand to 13–14% as backward integration kicks in; shipbuilding IPO adds INR1,000–1,500 crore valuation upside.
Continue reading “TITAGARH – Q3 FY26 Earnings Call – 16-Feb-26”

MAZDOCK – Q3 FY26 Earnings Call – 10-Feb-26

MAZDOCK’s topline: Structural defense tailwinds and order book visibility support 8–12% revenue CAGR, but execution risks cap upside; bottomline: EBITDA margins likely range-bound at 16–18% barring supply chain shocks; dividends: Sustainable at current payout ratios but vulnerable to capex trade-offs for next-gen projects.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) P17A/MPV deliveries on schedule; (2) MOD budget grows at 8–10% annually.
Outcome: Revenue CAGR of 8–10%, margins stable at 16–18%. Dividend growth tracks earnings (₹8–10/share annually). FX neutrality assumed.

Continue reading “MAZDOCK – Q3 FY26 Earnings Call – 10-Feb-26”

INDHOTEL – Q3 FY26 Earnings Call – 12-Feb-26

INDHOTEL: Findings imply sustained double-digit topline growth (12%–14%) with EBITDA margins at 39%–40% and PAT expansion (15%–18%), contingent on RevPAR resilience, acquisition execution, and capex discipline—structural diversification and asset-light scaling remain key differentiators.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • RevPAR Resilience: 8.5%–10% domestic RevPAR + 12%–14% consolidated revenue growth (60+ openings, F&B/spa upside). Taj Bandstand on track for ₹1,000 crore stabilization.
  • Acquisition Synergies: Ginger reaches 250+ hotels; Atmantan/Brij contribute ₹250–300 crore. EBITDA margin sustains at 39%–40%.
  • Implication: Double-digit PAT growth (15%–18%), management fee income grows high-teens, and capital-light model drives ROIC expansion.
Continue reading “INDHOTEL – Q3 FY26 Earnings Call – 12-Feb-26”

AMBER – Q3 FY26 Earnings Call – 10-Feb-26

AMBER’s topline resilience (13–15% Consumer Durables, 79% Electronics growth) and margin expansion (Electronics double-digit FY27) hinge on execution of INR 6,800 Cr capex pipeline and commodity pass-through, with structural risks skewed to integration delays and cyclical RAC demand.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: RAC industry flattish (Amber +13–15%) + Unitronics synergies materialize (H2’27) + KCC/Hosur on schedule.
  • Outcome: 25–30% consolidated revenue growth, Electronics EBITDA 10–12%, Sidwal +40% YoY. Margins expand 50–100 bps on pass-through and volume leverage.
Continue reading “AMBER – Q3 FY26 Earnings Call – 10-Feb-26”

TORNTPHARM – Q3 FY26 Earnings Call – 13-Feb-26

TORNTPHARM’s base case projects 12–14% CAGR driven by Brazil/U.S. execution and JB integration, with margins expanding to 33–34% by FY29. Outcomes hinge on GLP-1 timing, Germany resolution, synergy capture, and cost discipline, as structural tailwinds offset cyclical pricing pressures

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: (1) Ozempic launches in Brazil by late FY27; (2) JB synergies realize as guided (INR 400–450Cr by FY29).
  • Outcome: Brazil grows at 12–15% CAGR (ex-Semaglutide); U.S. hits $200M revenue by FY27 (20% CAGR). JB’s margin improves to 30% by FY28. Germany stabilizes by Q2 FY27; alternate supplier onboarded in 3 quarters.
  • Implications: Topline grows at 12–14% CAGR; EBITDA margins expand to 33–34% by FY29. Net debt/EBITDA targets achieved; interest expense declines to INR ~50Cr by FY29. FCF turns positive by FY28.
Continue reading “TORNTPHARM – Q3 FY26 Earnings Call – 13-Feb-26”

VBL (Varun Beverages) – Q3 FY26 Earnings Call – 3-Feb-26

VBL’s topline hinges on weather normalization and Twizza execution, with 10–15% growth probable; bottomline leverages operating scale and cost absorption, targeting 12–20% EPS upside; margins face cyclical realization pressure but structural backward integration supports 23–26% India EBITDA and 17–20% ex-India EBITDA by 2027.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Normal weather, Twizza synergies on track, snacks scale to ₹500cr.
  • Outcome: Volumes grow 10–12%; realization improves 2–3% on mix. India EBITDA margins sustain at 24–25%; ex-India margins expand to 17–18%. Free cash flow funds Twizza and brewery; dividend hike likely. Topline: +10–12%; Bottomline: +12–15%.
Continue reading “VBL (Varun Beverages) – Q3 FY26 Earnings Call – 3-Feb-26”